Difference between revisions of "Cytokeratin 5/6"
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
==Positive== | ==Positive== | ||
*[[Squamous cell carcinoma]]. | *[[Squamous cell carcinoma]]. | ||
**[[Squamous cell carcinoma of the lung]].<ref name=pmid26273374>{{Cite journal | last1 = Ma | first1 = Y. | last2 = Fan | first2 = M. | last3 = Dai | first3 = L. | last4 = Kang | first4 = X. | last5 = Liu | first5 = Y. | last6 = Sun | first6 = Y. | last7 = Xiong | first7 = H. | last8 = Liang | first8 = Z. | last9 = Yan | first9 = W. | title = Expression of p63 and CK5/6 in early-stage lung squamous cell carcinoma is not only an early diagnostic indicator but also correlates with a good prognosis. | journal = Thorac Cancer | volume = 6 | issue = 3 | pages = 288-95 | month = May | year = 2015 | doi = 10.1111/1759-7714.12181 | PMID = 26273374 }}</ref> | |||
*Benign prostate (basal cells).<ref name=pmid19605815>{{Cite journal | last1 = Trpkov | first1 = K. | last2 = Bartczak-McKay | first2 = J. | last3 = Yilmaz | first3 = A. | title = Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens. | journal = Am J Clin Pathol | volume = 132 | issue = 2 | pages = 211-20; quiz 307 | month = Aug | year = 2009 | doi = 10.1309/AJCPGFJP83IXZEUR | PMID = 19605815 }}</ref> | *Benign prostate (basal cells).<ref name=pmid19605815>{{Cite journal | last1 = Trpkov | first1 = K. | last2 = Bartczak-McKay | first2 = J. | last3 = Yilmaz | first3 = A. | title = Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens. | journal = Am J Clin Pathol | volume = 132 | issue = 2 | pages = 211-20; quiz 307 | month = Aug | year = 2009 | doi = 10.1309/AJCPGFJP83IXZEUR | PMID = 19605815 }}</ref> | ||
*[[Urothelial carcinoma]]. | *[[Urothelial carcinoma]]. | ||
Latest revision as of 02:18, 6 May 2016
Cytokeratin 5/6, abbreviated CK/5/6, is a common immunostain.
Use
- Prostatic adenocarcinoma versus high-grade prostatic intraepithelial neoplasia (HGPIN).
- CK5/6 marks the basal cells: present in HGPIN, absent in cancer.
- Urothelial cell carcinoma versus prostatic adenocarcinoma.
- Positive in UCC, negative in prostate adenocarcinoma.
Positive
- Squamous cell carcinoma.
- Benign prostate (basal cells).[2]
- Urothelial carcinoma.
- Malignant mesothelioma.[3]
- Reactive mesothelial cells.[4]
Negative
See also
References
- ↑ Ma, Y.; Fan, M.; Dai, L.; Kang, X.; Liu, Y.; Sun, Y.; Xiong, H.; Liang, Z. et al. (May 2015). "Expression of p63 and CK5/6 in early-stage lung squamous cell carcinoma is not only an early diagnostic indicator but also correlates with a good prognosis.". Thorac Cancer 6 (3): 288-95. doi:10.1111/1759-7714.12181. PMID 26273374.
- ↑ Trpkov, K.; Bartczak-McKay, J.; Yilmaz, A. (Aug 2009). "Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens.". Am J Clin Pathol 132 (2): 211-20; quiz 307. doi:10.1309/AJCPGFJP83IXZEUR. PMID 19605815.
- ↑ 3.0 3.1 Marchevsky AM (March 2008). "Application of immunohistochemistry to the diagnosis of malignant mesothelioma". Arch. Pathol. Lab. Med. 132 (3): 397-401. PMID 18318582. http://journals.allenpress.com/jrnlserv/?request=get-abstract&issn=0003-9985&volume=132&page=397.
- ↑ Yan, J.; Wei, Q.; Jian, W.; Liu, J.; Tang, H.; Ge, J.; Zhou, J.; Zhao, T. (2014). "A fine decision tree consisted of CK5/6, IMP3 and TTF1 for cytological diagnosis among reactive mesothelial cells, metastatic adenocarcinoma of lung and non-lung origin in pleural effusion.". Int J Clin Exp Pathol 7 (9): 5810-8. PMID 25337222.